The Brown University Child and Adolescent Psychopharmacology Update articles from November 2011

The Brown University Child and Adolescent Psychopharmacology Update archives from November 2011

Highlights ...
November 1, 2011... John Wiley & Sons, publisher of The Update, is very pleased to announce that we have been awarded the National Bronze Award for Newsletters in the General Excellence category by the American Society of Business Publication Editors.

Adding full CBT shows best response in pediatric SRI-partial responders with OCD.(POTS II)
November 1, 2011... For children and adolescents with obsessive-compulsive disorder (OCD) who are only partially responsive to treatment with serotonin reuptake inhibitors (SRIs), adding cognitive behavior therapy (CBT) to medication significantly reduced OCD...

Analysis: depression treatment response is influenced by the treatment calendar.(TORDIA)
November 1, 2011... An analysis of data from the Treatment of SSRI-Resistant Depression in Adolescents (TORDIA) study has found that the timing of when adolescent depression treatment begins and ends has a bearing on treatment response rates, with youths ending...

What are the latest recommendations for the psychopharmacological treatment of PTSD in children and adolescents?(Frequently Asked Questions)(Disease/Disorder overview)
November 1, 2011... Clinicians are treating posttraumatic stress disorder (PTSD) with a variety of medications and SSRIs are most commonly chosen. A review of the data done by Strawn et al. do not support the use of SSRIs as first-line treatments for PTSD in...

Stimulants increase heart rate in children with ADHD.(What's New In Research)
November 1, 2011... Ten years of follow-up data from the Multimodal Treatment Study of Children with ADHD (MTA) indicate that intensive and chronic use of stimulants does not increase the risk for high blood pressure in 7to 9-year-old children with...

Suicidal behaviors differ in antidepressant-treated early/late teens.(What's New In Research)
November 1, 2011... Suicidal behavior in adolescents prescribed antidepressants differs by age, with older adolescents having higher suicide rates than younger adolescents. Although there are many features shared in early and late adolescent suicidal behavior,...

Low use of MH services for minority children with ADHD.(News Notes)(Clinical report)
November 1, 2011... Parents' medication concerns were associated with less follow-up at mental health appointments for minority children with attention-deficit/hyperactivity disorder (ADHD). In a longitudinal cohort study conducted at a New York City hospital,...

Creatine in female teens with SSRI-resistant depression.(News Notes)
November 1, 2011... Eight weeks of adjunctive creatine 4 g/day significantly reduced depressive symptoms in female adolescents with major depressive disorder (MDD) resistant to treatment with a selective serotonin reuptake inhibitor (SSRI), according to a small,...

Periodic limb movements of sleep in SSRI-treated children.(News Notes)
November 1, 2011... Children treated with selective serotonin reuptake inhibitors (SSRIs) are at higher risk of periodic limb movements of sleep than children not receiving SSRIs, according to a retrospective review of polysomnography data of more than 1,000...

Oculogyric crises induced by low-dose risperidone.(Case Report)
November 1, 2011... Patient: Male, 15 years old Case: A 15-year-old boy with mental retardation, autistic disorder, and Tourette Syndrome presented with self-injury (hitting his nose 20 to 50 times an hour), vocal tics (yelling at a high pitch 100 to 200 times...

Milnacipran post-marketing adverse events.(From the FDA)(Brief article)
November 1, 2011... Postmarketing drug evaluations report adverse events for milnacipran (Savella), with heart rates and elevated blood pressure possibly greater than that reflected in current labeling. The FDA has yet to determine if the current Warnings and...

New labeling changes.(From the FDA)
November 1, 2011... Newly approved labeling revisions for September include duloxetine (Cymbalta), iloperidone (Fanapt), ondansetron (Zofran), vilazodone (Viibyrd), risperidone (Risperdal), paliperidone (Invega Sustenna), pimozide (Orap), and zolpidem (Zolpimist)....

Reviews of pediatric studies.(From the FDA)
November 1, 2011... Updated medical, statistical, and clinical pharmacologic reviews of pediatric studies include the following drugs: aripiprazole, dexmethylphenidate, divalproex, guanfacine, lamotrigine, levetiracetam, lisdexamfetamine, methylphenidate...